1-(4-methoxyphenyl)piperazine (MeOPP)

Expert peer review on pre-review report

35th Expert Committee on Drug Dependence, Hammamet, Tunisia
June 4-8, 2012
1. Comment based on the review report

a. Evidence on dependence and abuse potential
   Based on the report there is no study data available to determine the abuse and dependency potential of 1-(-4-methoxyphenyl)piperazine (MeOPP).

b. Consequences to individual and society because of misuse
   The use of MeOPP appears to be associated with situations similar to those of “Ecstasy” or with users who are seeking effects similar to those of “Ecstasy” (MDMA in particular) and therefore instances of misuse, abuse and dependence would be limited to such individuals rather than the general population.

c. Magnitude of the problem in countries (misuse, illicit production, smuggling etc)
   In the report on the WHO questionnaire for review of psychoactive substances three countries reported that MeOPP is controlled under legislation that is intended to regulate availability of substances of abuse. While not included in the Standard for the uniform scheduling of Drugs and Poisons, the possession and supply of MeOPP is subject to control in certain Australian States and Territories, as a controlled substance. In Japan MeOPP is controlled as designated substances under the Pharmaceutical Affairs Law since April 2007.

   It is alluded to in the report on the WHO questionnaire for the review of psychoactive substances for the 35th ECDD that Denmark has reported 3 seizures from 2005 to 2007 and that its use is limited and rather harmful. Seventeen (17) countries reported that it is not used in a harmful way and a further thirteen (13) countries indicated that its use is unknown.

d. Need of the substance for medical (including veterinary) practice
   'There is no clear medical or veterinary use'

e. Need of the substance for other purposes (e.g. industrial)
   There is no information available on the use of MeOPP, a piperazine derivative in industry.

f. Measures taken by countries to curb misuse
   In the report on the WHO questionnaire for review of psychoactive substances three countries reported that MeOPP is controlled under legislation that is intended to regulate availability of substances of abuse. The possession and supply of MeOPP is subject to control in certain Australian States and Territories, as a controlled substance. In Japan MeOPP is controlled as designated substances under the Pharmaceutical Affairs Law since April 2007.

g. Impact if this substance is scheduled
35th ECDD Agenda item 5.3d

Expert peer review on pre-review report

No information available